HPS Pharmacies wish to provide an update regarding the Therapeutic Goods Administration advice on supply shortages of:
BCG (Bacillus Calmette – Guérin)
|Brand||BCG Vaccine, Sanofi-Aventis||ImmuCyst®, Sanofi-Aventis||OncoTICE®, MSD Australia|
|Doses||1.5mg multidose vial||6.6 to 19.2 x hundred million CFU||65 hundred million CFU|
|Expected Return Date||1 Dec 2016||30 Sep 2015||Limited availability|
The interruptions to supply of BCG (Bacillus Calmette – Guérin) powder for injections are due to manufacturing issues and are expected to be resolved as noted above.
Sanofi-Aventis have no stock available of either BCG Vaccine or ImmuCyst®, and have not been able to source substitute medicines under Section 19(A) as previously indicated.
Whilst the availability of OncoTICE® has been constrained to emergency requirements, HPS Pharmacies are now able to access supplies to meet individual patient needs.
Please retain this notice in a prominent position, including in other related business units as a reminder for all staff members until supply returns to normal.
Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your Pharmacist at HPS Pharmacies, Sanofi-Aventis Australia on 1800 829 468, or Merck Sharp & Dohme Australia on 02 8988 8428.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.